Tan AR - Search Results

1

Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.

Tan AR, Yang X, Hewitt SM, Berman A, Lepper ER, Sparreboom A, Parr AL, Figg WD, Chow C, Steinberg SM, Bacharach SL, Whatley M, Carrasquillo JA, Brahim JS, Ettenberg SA, Lipkowitz S, Swain SM. Tan AR, et al. J Clin Oncol. 2004 Aug 1;22(15):3080-90. doi: 10.1200/JCO.2004.08.189. J Clin Oncol. 2004. PMID: 15284258

2

Adjuvant chemotherapy for breast cancer: an update.

Tan AR, Swain SM. Tan AR, et al. Semin Oncol. 2001 Aug;28(4):359-76. doi: 10.1016/s0093-7754(01)90130-7. Semin Oncol. 2001. PMID: 11498830 Review.

3

Novel agents: clinical trial design.

Tan AR, Swain SM. Tan AR, et al. Semin Oncol. 2001 Oct;28(5 Suppl 16):148-53. doi: 10.1016/s0093-7754(01)90292-1. Semin Oncol. 2001. PMID: 11706406 Review.

4

Review of flavopiridol, a cyclin-dependent kinase inhibitor, as breast cancer therapy.

Tan AR, Swain SM. Tan AR, et al. Semin Oncol. 2002 Jun;29(3 Suppl 11):77-85. doi: 10.1053/sonc.2002.34059. Semin Oncol. 2002. PMID: 12138401 Review.

5

Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms.

Tan AR, Headlee D, Messmann R, Sausville EA, Arbuck SG, Murgo AJ, Melillo G, Zhai S, Figg WD, Swain SM, Senderowicz AM. Tan AR, et al. J Clin Oncol. 2002 Oct 1;20(19):4074-82. doi: 10.1200/JCO.2002.01.043. J Clin Oncol. 2002. PMID: 12351605 Clinical Trial.

6

Liquid-chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor.

Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A. Lepper ER, et al. Among authors: tan ar. J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Oct 25;796(1):181-8. doi: 10.1016/j.jchromb.2003.08.015. J Chromatogr B Analyt Technol Biomed Life Sci. 2003. PMID: 14552829

7

Ongoing adjuvant trials with trastuzumab in breast cancer.

Tan AR, Swain SM. Tan AR, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):54-64. doi: 10.1053/j.seminoncol.2003.08.008. Semin Oncol. 2003. PMID: 14613027 Review.

8

Phase I trial of the cyclin-dependent kinase inhibitor flavopiridol in combination with docetaxel in patients with metastatic breast cancer.

Tan AR, Yang X, Berman A, Zhai S, Sparreboom A, Parr AL, Chow C, Brahim JS, Steinberg SM, Figg WD, Swain SM. Tan AR, et al. Clin Cancer Res. 2004 Aug 1;10(15):5038-47. doi: 10.1158/1078-0432.CCR-04-0025. Clin Cancer Res. 2004. PMID: 15297405 Clinical Trial.

9

Gene expression patterns and profile changes pre- and post-erlotinib treatment in patients with metastatic breast cancer.

Yang SX, Simon RM, Tan AR, Nguyen D, Swain SM. Yang SX, et al. Among authors: tan ar. Clin Cancer Res. 2005 Sep 1;11(17):6226-32. doi: 10.1158/1078-0432.CCR-05-0270. Clin Cancer Res. 2005. PMID: 16144925

10

A pilot study to evaluate the vascular endothelial growth factor receptor tyrosine kinase inhibitor AZD2171 and chemotherapy in locally advanced and inflammatory breast cancer.

Denduluri N, Tan AR, Walshe J, Berman A, Yang SX, Chow CK, Swain SM. Denduluri N, et al. Among authors: tan ar. Clin Breast Cancer. 2005 Dec;6(5):460-3. doi: 10.3816/CBC.2005.n.052. Clin Breast Cancer. 2005. PMID: 16381631 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

131 results

Search Page

Filters